Clinical Trials Directory

Trials / Terminated

TerminatedNCT00774306

Antiepileptic Drugs and Vascular Risk Markers

The Effects of Antiepileptic Drugs on Serum Lipids and Inflammation in Patients With Subarachnoid Hemorrhage

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
52 (actual)
Sponsor
Thomas Jefferson University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if certain seizure medications raise levels of cholesterol and other blood components which could increase the risk of heart attacks and strokes.

Detailed description

There is some evidence that certain seizure medicines may raise levels of cholesterol and other blood components which could increase the risk of heart attacks and strokes, however, more research is needed. Individuals with acute subarachnoid hemorrhage traditionally are treated with seizure medicines, but it is not clear which one is best, or if any such medication is necessary at all. This study is intended to find out if certain seizure medications raise levels of cholesterol and other blood components which could lead to an increased risk of heart attacks and strokes. In this study, 200 people with acute subarachnoid hemorrhage will be randomized to treatment with one of three different seizure medicines-phenytoin, valproate, or levetiracetam-or to receive no seizure medication at all. In each participant, cholesterol and other blood markers that relate to heart attack and stroke risk will be measured shortly after hospital admission and again 8 weeks later. At the 8-week point most participants will have their seizure medication discontinued, and the same blood tests will be repeated. Information from this study could lead to changes in how seizure medications are prescribed both in the subarachnoid hemorrhage population and in other people who are prone to seizures.

Conditions

Interventions

TypeNameDescription
DRUGphenytoinPhenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
DRUGvalproateValproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
DRUGlevetiracetamLevetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.

Timeline

Start date
2009-04-01
Primary completion
2012-06-01
Completion
2012-06-01
First posted
2008-10-17
Last updated
2017-12-18
Results posted
2014-11-25

Source: ClinicalTrials.gov record NCT00774306. Inclusion in this directory is not an endorsement.

Antiepileptic Drugs and Vascular Risk Markers (NCT00774306) · Clinical Trials Directory